...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Trillium
7
Aug 23, 2021 01:03PM
5
Aug 25, 2021 11:20AM
7
Aug 25, 2021 10:23PM
6
Aug 26, 2021 09:32AM
4
Aug 26, 2021 11:11AM
5
Aug 26, 2021 11:25AM

I'd be happy with a $10 CVR deal with more to come based on milestones.

Not me.  I'd much rather wait it out.  With a CVR deal, risk is transferred from the acquirer to shareholders.  No liquidity.  If milestones aren't reached, or are reached too late, we get nothing.  I'd call that a great incentive to delay, delay, delay.  Pretty much a total disaster IMO.

3
Aug 26, 2021 02:45PM
2
Aug 26, 2021 07:18PM
6
Aug 28, 2021 08:17AM
Share
New Message
Please login to post a reply